Literature DB >> 25074540

Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas.

Sanne A M van Lith1, Remco Molenaar1, Cornelis J F van Noorden1, William P J Leenders1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25074540      PMCID： PMC4232089          DOI： 10.1093/neuonc/nou152

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?

Authors:  Jacob G Scott; David Basanta; Prakash Chinnaiyan; Peter Canoll; Kristen R Swanson; Alexander R A Anderson
Journal:  Neuro Oncol       Date:  2011-07-22       Impact factor: 12.300

Review 2.  Glutamine addiction: a new therapeutic target in cancer.

Authors:  David R Wise; Craig B Thompson
Journal:  Trends Biochem Sci       Date:  2010-08       Impact factor: 13.807

3.  Vesicular release of glutamate from unmyelinated axons in white matter.

Authors:  Jennifer L Ziskin; Akiko Nishiyama; Maria Rubio; Masahiro Fukaya; Dwight E Bergles
Journal:  Nat Neurosci       Date:  2007-02-11       Impact factor: 24.884

4.  The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo.

Authors:  John F de Groot; Ta Jen Liu; Gregory Fuller; W K Alfred Yung
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

5.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

6.  Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.

Authors:  Anne L Baldock; Kevin Yagle; Donald E Born; Sunyoung Ahn; Andrew D Trister; Maxwell Neal; Sandra K Johnston; Carly A Bridge; David Basanta; Jacob Scott; Hani Malone; Adam M Sonabend; Peter Canoll; Maciej M Mrugala; Jason K Rockhill; Russell C Rockne; Kristin R Swanson
Journal:  Neuro Oncol       Date:  2014-06       Impact factor: 12.300

Review 7.  Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?

Authors:  Sanne A M van Lith; Anna C Navis; Kiek Verrijp; Simone P Niclou; Rolf Bjerkvig; Pieter Wesseling; Bastiaan Tops; Remco Molenaar; Cornelis J F van Noorden; William P J Leenders
Journal:  Biochim Biophys Acta       Date:  2014-04-18

Review 8.  The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.

Authors:  Remco J Molenaar; Tomas Radivoyevitch; Jaroslaw P Maciejewski; Cornelis J F van Noorden; Fonnet E Bleeker
Journal:  Biochim Biophys Acta       Date:  2014-05-28
  8 in total
  10 in total

Review 1.  Molecular and Genetic Determinants of Glioma Cell Invasion.

Authors:  Kenta Masui; Yoichiro Kato; Tatsuo Sawada; Paul S Mischel; Noriyuki Shibata
Journal:  Int J Mol Sci       Date:  2017-12-04       Impact factor: 6.208

2.  In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.

Authors:  Mohammed Khurshed; Remco J Molenaar; Krissie Lenting; William P Leenders; Cornelis J F van Noorden
Journal:  Oncotarget       Date:  2017-07-25

Review 3.  Wild-type and mutated IDH1/2 enzymes and therapy responses.

Authors:  Remco J Molenaar; Jaroslaw P Maciejewski; Johanna W Wilmink; Cornelis J F van Noorden
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 8.756

Review 4.  Glioma: experimental models and reality.

Authors:  Krissie Lenting; Roel Verhaak; Mark Ter Laan; Pieter Wesseling; William Leenders
Journal:  Acta Neuropathol       Date:  2017-01-10       Impact factor: 17.088

Review 5.  Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?

Authors:  Cornelis J F van Noorden; Vashendriya V V Hira; Amber J van Dijck; Metka Novak; Barbara Breznik; Remco J Molenaar
Journal:  Cells       Date:  2021-03-22       Impact factor: 6.600

6.  A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.

Authors:  Mohammed Khurshed; Remco J Molenaar; Myra E van Linde; Ron A Mathôt; Eduard A Struys; Tom van Wezel; Cornelis J F van Noorden; Heinz-Josef Klümpen; Judith V M G Bovée; Johanna W Wilmink
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

7.  Determination of phosphate-activated glutaminase activity and its kinetics in mouse tissues using metabolic mapping (quantitative enzyme histochemistry).

Authors:  Dennis Botman; Wikky Tigchelaar; Cornelis J F Van Noorden
Journal:  J Histochem Cytochem       Date:  2014-08-27       Impact factor: 2.479

8.  Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.

Authors:  Sanne A M van Lith; Anna C Navis; Krissie Lenting; Kiek Verrijp; Jan T G Schepens; Wiljan J A J Hendriks; Nil A Schubert; Hanka Venselaar; Ron A Wevers; Arno van Rooij; Pieter Wesseling; Remco J Molenaar; Cornelis J F van Noorden; Stefan Pusch; Bastiaan Tops; William P J Leenders
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379

9.  Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Authors:  Remco J Molenaar; Robert J S Coelen; Mohammed Khurshed; Eva Roos; Matthan W A Caan; Myra E van Linde; Mathilde Kouwenhoven; Jos A M Bramer; Judith V M G Bovée; Ron A Mathôt; Heinz-Josef Klümpen; Hanneke W M van Laarhoven; Cornelis J F van Noorden; W Peter Vandertop; Hans Gelderblom; Thomas M van Gulik; Johanna W Wilmink
Journal:  BMJ Open       Date:  2017-06-10       Impact factor: 3.006

10.  Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma.

Authors:  Chao Sun; Liming Xiao; Yuanlin Zhao; Jiankuan Shi; Yuan Yuan; Yu Gu; Feng Zhang; Xing Gao; Ying Yang; Risheng Yang; Junhui Qin; Jin Zhang; Chao Wang; Yingmei Wang; Zhe Wang; Peizhen Hu; Ting Chang; Liang Wang; Gang Wang; Huangtao Chen; Zhuyi Li; Jing Ye
Journal:  Transl Oncol       Date:  2020-03-21       Impact factor: 4.243
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.